Press releases

Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming...

The Institut Pasteur will provide a selection of strains for the DEINOVE platform to evaluate their potential antibiotic and antifungal...

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...

The robotic platform for extracting and screening antibiotic activities from bacterial strains is now operational for the analysis of...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

The test design has been improved for a better assessment of DNV3837 effectiveness in treating Clostridium difficile infections, This will...

The new DEINOVE website displays an updated presentation of DEINOVE’s corporate activities and identity It illustrates the disruptive...

After launching Phyt-N-Resist® in 2018, Deinove is developing on its own a 2 nd innovative bio-based carotenoid for the cosmetics market...

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...

CALIBR is a division of the Scripps Research, a California non-profit corporation, dedicated to finding new treatments addressing unmet...